a claimed salt of alendronic acid in merck's patent (claim 23) is 4-amino-1-hydroxybutylidene-1, 1-bisphosphonic acid monosodium salt trihydrate ("amt").
that is, a monosodium salt version of the acid.
the second applicant, merck sharp &amp; dohme (australia) pty ltd carries on in australia the business of formulation, sale and distribution of pharmaceutical products.